Vytrus Biotech, S.A. (FRA:V5P)

Germany · Delayed Price · Currency is EUR

15.00

+0.60 (4.17%)

Last updated: Oct 23, 2026, 3:25 PM CEST

Market Cap	113.50M +155.7%
Revenue (ttm)	9.69M +59.1%
Net Income	2.90M +183.7%
EPS	0.39 +184.0%
Shares Out	n/a
PE Ratio	38.92
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51
Open	13.90
Previous Close	14.40
Day's Range	13.90 - 15.00
52-Week Range	5.45 - 21.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Mar 25, 2027

About Vytrus Biotech

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin’s regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and protects ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2009

Employees 44

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol V5P

Financial Performance

In 2025, Vytrus Biotech's revenue was 9.69 million, an increase of 59.15% compared to the previous year's 6.09 million. Earnings were 2.90 million, an increase of 183.70%.

Financial Statements